The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Aug. 23, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 88	$ 72
Patents and Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years
Maximum [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	23 years
Minimum [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	16 years
RubrYc Theraputics, Inc. [Member] \| Immune-Oncology Antibodies (RTX-003) [Member]
Finite-Lived Intangible Assets [Line Items]
Investment			$ 7,500